Cryptosporidium polyclonal antibody

Drug Profile

Cryptosporidium polyclonal antibody

Alternative Names: BWPT 301; Immuno-C

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator Biomune Systems
  • Class Polyclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cryptosporidiosis

Most Recent Events

  • 24 Jan 2017 Discontinued - Phase-II for Cryptosporidiosis in USA (Parenteral)
  • 27 Nov 2000 Suspended-II for Cryptosporidiosis in USA (Parenteral)
  • 14 Sep 1995 Phase-II clinical trials for Cryptosporidiosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top